

IN THE CLAIMS

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)

35. (canceled)

36. (previously presented) A method for regenerating in vivo mammal tissue comprising applying in vivo to the site requiring such a treatment a biocompatible biomaterial containing at least one hyaluronic acid derivative selected from the group consisting of esters of hyaluronic acid wherein part or all of the carboxy functions are esterified with alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, said hyaluronic acid derivative being processed in the form of a three-dimensional structure enclosing hollow spaces formed by communicating pores and/or fine fibres or microfibrils entangled together, wherein:

i) said biomaterial is free from cellular components and/or products thereof,

ii) when said hyaluronic acid derivative is processed in the form of non woven tissue, it is a hyaluronic acid partial ester with benzyl and has an esterification degree of 65%.

37. (original) The method according to claim 36, wherein said mammal tissue is human tissue selected from the group consisting of epidermal, dermal, bone, cartilage, nerve, cardiovascular, adipose and hepatic tissues.

38. (canceled)

39. (canceled)

40. (canceled)

41. (previously presented) The method according to claim 36, wherein said hyaluronic acid derivative is a hyaluronic acid ester with benzyl alcohol.

42. (original) The method according to claim 36, wherein said biocompatible biomaterial consists essentially of said hyaluronic

acid derivatives in the form of three-dimensional structures with communicating hollow spaces created by pores and/or fine fibres or microfibrils entangled together.

43. (original) The method according to claim 36, wherein said biocompatible biomaterial further comprises at least another biocompatible natural, semisynthetic and/or synthetic polymer.

44. (original) The method according to claim 36, wherein said biocompatible biomaterial further contains pharmaceutically or biologically active substances.

45. (original) The method according to claim 36, wherein said biocompatible biomaterial further contains inside the non-woven fabrics, cords and liophylic compositions.